Glucokinase as a therapeutic target based on findings from the analysis of mouse models

Area of Science:

• Endocrinology
• Metabolic Diseases
• Molecular Biology

Background:

• Type 2 diabetes is characterized by decreased pancreatic beta-cell function and mass.
• Glucokinase plays a critical role in beta-cell expansion in response to dietary changes.
• Understanding glucokinase's role is crucial for developing effective type 2 diabetes treatments.

Purpose of the Study:

• To elucidate the pathophysiology of type 2 diabetes with a focus on glucokinase.
• To establish a new treatment strategy targeting glucokinase.
• To investigate the differential mechanisms of beta-cell proliferation under various dietary conditions.

Main Methods:

• Utilized mouse models, including db/db mice, to study type 2 diabetes.
• Administered glucokinase activators and inactivators to assess their effects.
• Analyzed beta-cell function, mass, glucose tolerance, and hepatic fat accumulation.

Main Results:

• Short-term high-fat diet-induced beta-cell proliferation occurs via a glucokinase-independent pathway.
• Sub-chronic glucokinase activator administration in db/db mice led to transient hypoglycemia and hepatic fat accumulation without improving beta-cell function.
• Inactivating glucokinase in beta-cells prevented beta-cell failure and improved glucose tolerance in db/db mice.

Conclusions:

• Glucokinase activity significantly influences type 2 diabetes pathophysiology.
• Targeting glucokinase, particularly through inactivation in beta-cells, shows therapeutic potential for type 2 diabetes.
• Distinct pathways regulate beta-cell proliferation in response to short-term versus long-term dietary challenges.